Table 1: Prognostic factors for patients presenting with brain metastases.
|
Factor |
Tumor site |
|
Age |
Common |
|
Gender |
Common |
|
Performance status |
Common |
|
Location of BM |
Common |
|
Number of BM |
Common |
|
Size of BM |
Common |
|
BM velocity |
Common |
|
Volume of BM |
Common |
|
Neurologic deficit status |
Common |
|
Extracranial disease status |
Common |
|
Histology of BM |
Radioresistant vs. radiosensitive |
|
ER/PR status |
Breast |
|
HER-2 status |
Breast |
|
EGFR status |
Non-small cell lung |
|
EML4-ALK status |
Non-small cell lung |
|
BRAF status |
Malignant melanoma |
|
Caveolin-1 |
Non-small cell lung |
|
Peritumoral edema status |
Common |
|
Radiologic features |
Common |
|
Interval from primary diagnosis |
Common |
|
Radiotherapy technique (SRS vs. others) |
Common |
|
Type of systemic therapy |
Non-small cell lung, breast, malignant melanoma |
BM: Brain metastasis; ER: Estrogen receptor; PR: Progesteron receptor; HER-2: Human epidermal growth factor receptor 2; EML4-ALK: Echinoderm microtubule associated protein-like 4 and anaplastic lymphoma kinase; BRAF: v-Raf murine sarcoma viral oncogene homolog B.